CD274 and non-small cell lung carcinoma: However, the responsiveness to anti–PD-1/PD-L1 agents is relatively dismal in patients with PD-L1lo/– NSCLC, which could be attributed to alternative immunosuppressive pathways in PD-L1lo/– tumors that remain poorly understood.